Sanofi (EPA:SAN) received a €80.00 ($95.24) price objective from investment analysts at Jefferies Group in a note issued to investors on Tuesday. The brokerage presently has a “neutral” rating on the stock. Jefferies Group’s price target indicates a potential upside of 9.07% from the stock’s previous close.

SAN has been the subject of a number of other research reports. Morgan Stanley set a €92.00 ($109.52) price target on Sanofi and gave the company a “buy” rating in a research note on Friday, October 6th. Goldman Sachs Group set a €82.00 ($97.62) price target on Sanofi and gave the company a “neutral” rating in a research note on Friday, November 3rd. set a €78.00 ($92.86) price target on Sanofi and gave the company a “neutral” rating in a research note on Friday, November 3rd. UBS Group set a €82.00 ($97.62) price target on Sanofi and gave the company a “neutral” rating in a research note on Monday, October 23rd. Finally, Deutsche Bank set a €96.00 ($114.29) price target on Sanofi and gave the company a “buy” rating in a research note on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of €87.06 ($103.65).

Sanofi (EPA SAN) opened at €73.35 ($87.32) on Tuesday. The stock has a market capitalization of $92,650.00 and a PE ratio of 20.32. Sanofi has a 12 month low of €71.06 ($84.60) and a 12 month high of €92.97 ($110.68).

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/16/sanofi-san-pt-set-at-80-00-by-jefferies-group.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.